TOI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncology Institute Inc (TOI) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company has demonstrated strong revenue growth, a positive analyst outlook with a raised price target, and a promising inflection point in its business model. While there are some concerns regarding hedge fund selling and negative net income, the long-term potential outweighs these risks.
The stock is in a neutral technical position. The MACD is positive but contracting, RSI is neutral at 40.207, and moving averages are converging. The pre-market price of $3.35 is above the pivot level of $3.343, indicating potential upward momentum. Key resistance levels are at $3.633 and $3.812, while support levels are at $3.053 and $2.874.
Analyst upgrade with a raised price target to $8 and a Buy rating.
First profitable quarter as a public company in Q4
Management's reiterated guidance of $630M-$650M revenue for 2026, with significant growth in capitated revenue.
Pre-market price increase of 2.45%, signaling positive sentiment.
Hedge funds are selling, with a significant increase in selling activity (47487.34% over the last quarter).
Negative net income and declining EPS in the latest quarter.
No recent news or congress trading data to support additional momentum.
In Q4 2025, revenue increased by 41.58% YoY to $141.96M, gross margin improved by 15.52% YoY to 14.89%, but net income dropped by 40.63% YoY to -$6.43M, and EPS declined by 57.14% YoY to -$0.06.
B. Riley raised the price target on TOI to $8 from $6 and maintained a Buy rating. The analyst highlighted the company's first profitable quarter and significant growth potential from new contracts and payer wins, signaling a positive long-term outlook.
